$6.59
4.08% today
Nasdaq, Apr 02, 09:15 pm CET
ISIN
BE0974358906
Symbol
NYXH

Nyxoah SA Stock price

$6.87
-3.04 30.68% 1M
-2.36 25.53% 6M
-1.13 14.13% YTD
-5.39 43.96% 1Y
-11.76 63.12% 3Y
-12.63 64.77% 5Y
-12.63 64.77% 10Y
Nasdaq, Closing price Tue, Apr 01 2025
-0.11 1.58%
ISIN
BE0974358906
Symbol
NYXH
Sector

Key metrics

Market capitalization $236.24m
Enterprise Value $171.11m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 34.99
P/S ratio (TTM) P/S ratio 48.31
P/B ratio (TTM) P/B ratio 2.19
Revenue growth (TTM) Revenue growth 4.08%
Revenue (TTM) Revenue $4.89m
EBIT (operating result TTM) EBIT $-64.66m
Free Cash Flow (TTM) Free Cash Flow $-51.87m
Cash position $88.59m
EPS (TTM) EPS $-1.95
P/E forward negative
P/S forward 11.36
EV/Sales forward 8.23
Short interest 0.24%
Show more

Is Nyxoah SA a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

Nyxoah SA Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Nyxoah SA forecast:

7x Buy
78%
2x Hold
22%

Analyst Opinions

9 Analysts have issued a Nyxoah SA forecast:

Buy
78%
Hold
22%

Financial data from Nyxoah SA

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
4.89 4.89
4% 4%
100%
- Direct Costs 4.62 4.62
6% 6%
94%
0.27 0.27
25% 25%
6%
- Selling and Administrative Expenses 26 26
34% 34%
538%
- Research and Development Expense 36 36
30% 30%
730%
-62 -62
32% 32%
-1,262%
- Depreciation and Amortization 2.94 2.94
15% 15%
60%
EBIT (Operating Income) EBIT -65 -65
31% 31%
-1,322%
Net Profit -64 -64
37% 37%
-1,310%

In millions USD.

Don't miss a Thing! We will send you all news about Nyxoah SA directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Nyxoah SA Stock News

Neutral
GlobeNewsWire
2 days ago
Investors can contact the law firm at no cost to learn more about recovering their losses
Neutral
GlobeNewsWire
8 days ago
INSIDE INFORMATION REGULATED INFORMATION FDA Issues Nyxoah an Approvable Letter for its Genio® System Mont-Saint-Guibert, Belgium – March 26, 2025, 8:00am CET / 3:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the U.S. Food and Drug...
AD HOC NEWS
8 days ago
Nyxoah SA. / BE0974358906
More Nyxoah SA News

Company Profile

Nyxoah SA engages in the research and development, manufacture and sale of medical devices. It focuses on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. Its lead solution platform is based on the Genio system, a validated, user-centered, neurostimulation therapy for obstructive sleep apnea (OSA). The company was founded by Robert Taub and Adi Mashiach on July 15, 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Head office Belgium
CEO Olivier Taelman
Employees 183
Founded 2009
Website www.nyxoah.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today